Abstract: The present invention relates to a compound of formula (I): (I) as defined in the description. The present invention also relates to a method for extracting biological membrane-associated membrane proteins, comprising a step of bringing an aqueous solution of biological membrane-associated membrane proteins into contact with at least one compound of the invention. The present invention also relates to a method for stabilizing membrane proteins in solution in an aqueous solution, comprising a step (i) consisting in bringing an aqueous solution of a membrane protein in solution into contact with at least one compound of the invention.

Abstract: A compound of formula (I): or pharmaceutically acceptable enantiomer, salt or solvate thereof, or a mixture thereof, the ring A, and the substituents Z, Y and R1 being as defined herein.

Abstract: The present invention relates to a compound of formula (I): (I) as defined in the description. The present invention also relates to a method for extracting biological membrane-associated membrane proteins, comprising a step of bringing an aqueous solution of biological membrane-associated membrane proteins into contact with at least one compound of the invention. The present invention also relates to a method for stabilizing membrane proteins in solution in an aqueous solution, comprising a step (i) consisting in bringing an aqueous solution of a membrane protein in solution into contact with at least one compound of the invention.

Abstract: The present invention relates to a method for selectively extracting membrane proteins using at least one calixarene of formula (I). The use of calixarenes in the method according to the invention enables the selective solubilization of the membrane proteins while preserving the three-dimensional structure that is essential to the enzymatic activity thereof.

Abstract: The invention relates to a compound having structure (I), which acts as a non-competitive specific inhibitor of P-glycoprotein (P-gp for “Pleiotropic glycoprotein”) and which can be used as a drug, particularly for improving the effectiveness of chemotherapy treatments. The invention is therefore suitable for use in the medical field, particularly for the chemotherapeutic treatment of cancers or infections.

Abstract: The present invention relates to a method for selectively extracting membrane proteins using at least one calixarene of formula (I). The use of calixarenes in the method according to the invention enables the selective solubilization of the membrane proteins while preserving the three-dimensional structure that is essential to the enzymatic activity thereof.

Abstract: The present invention relates to a system for expressing toxic proteins, to an expression vector comprising this system, to a prokaryotic cell transformed with this system, and also to a method for synthesizing a toxic protein using this expression system. The expression system of the invention is characterized in that it comprises successively, in the 5?-3? direction, a nucleotide sequence encoding the Asp-Pro dipeptide and a nucleotide sequence encoding a toxic protein. According to a preferred embodiment of the invention, the expression system also comprises, upstream of the Asp-Pro sequence, a nucleotide sequence encoding a soluble protein. The expression system of the invention makes it possible to construct an expression vector that is useful for transforming a prokaryotic cell such as E. coli, for example in a method for synthesizing the toxic protein.

Abstract: The present invention discloses a vector for the coexpression of membrane domains of the envelope proteins of a virus, and also a method for producing homo- and/or hetero-oligomers of these domains. This vector comprises at least one region for replication and for maintenance of said vector in the host cell; a first region consisting successively, in said direction of translation of the vector, of a first promoter followed by a first sequence encoding a first chimeric protein comprising in particular a sequence encoding one of said at least two membrane domains; and a second region consisting successively, in said direction of translation of the vector, of a second promoter followed by a second sequence encoding a second chimeric protein comprising in particular a sequence encoding the other of said at least two membrane domains. The present invention is useful for the production of medicinal products for the treatment or prophylaxis of hepatitis C.

Abstract: The present invention relates to a system for expressing toxic proteins, to an expression vector comprising this system, to a prokaryotic cell transformed with this system, and also to a method for synthesizing a toxic protein using this expression system. The expression system of the invention is characterized in that it comprises successively, in the 5?-3? direction, a nucleotide sequence encoding the Asp-Pro dipeptide and a nucleotide sequence encoding a toxic protein. According to a preferred embodiment of the invention, the expression system also comprises, upstream of the Asp-Pro sequence, a nucleotide sequence encoding a soluble protein. The expression system of the invention makes it possible to construct an expression vector that is useful for transforming a prokaryotic cell such as E. coli, for example in a method for synthesizing the toxic protein.